Ernesto Bertarelli inherited control of Serono from a multigenerational family pharmaceutical business, then expanded the company sharply before its sale to Merck and redeployed the proceeds into a diversified investment portfolio. [1][2]
Serono was an inherited business with deep family roots
Bertarelli did not start Serono. His grandfather Pietro became the company's managing director in 1935, his father Fabio later became chief executive, and the family remained closely tied to the business for decades before Ernesto's leadership. [2]
Ernesto became Serono's chief executive before inheriting ownership with his sister Dona after their father's death in 1998. That sequence matters because his wealth began from an already valuable operating company rather than from independently raised startup capital. [1][2]
Under the siblings' ownership, Serono grew into a much larger biotechnology company. Forbes reports that revenues reached roughly $2.4 billion before the family sold the company to Merck for more than $13 billion in 2007. [1]
The Serono sale converted inherited control into diversified capital
The sale transformed a concentrated family-company stake into a large pool of liquid capital. The Bertarelli family subsequently invested across life sciences, real estate and other businesses, extending the fortune beyond the company that originally created it. [1][2]
Serono's sale price was not Bertarelli's personal proceeds because ownership was shared with family members and transaction value applied to the whole company. His fortune reflects both the substantial business he inherited and the additional value created during his tenure before that ownership was converted into a broader investment portfolio. [1][2]
Sources for background
Sources reviewed Sep 17, 2026.
- Ernesto Bertarelli · Forbes · Mar 10, 2026
- Three Generations · Bertarelli
Comparable Healthcare billionaires
Similar Healthcare billionaires by estimated net worth.
